We’ve been committed to the ongoing international fight against yellow fever for 70 years, delivering half a billion doses of vaccines and seeking innovations for the future. Sanofi is part of the EYE ...

The Sanofi of today is built on a heritage of turning the impossible into the possible for people and communities around the globe. In the last half century, Sanofi has grown into one of the world’s ...

We chase the miracles of science to improve people’s lives. But we can’t do it alone. We work closely with healthcare professionals, patient advocates, governments and industry so we can have the ...

For over 45 years, Sanofi has been at the forefront of combating meningococcal epidemics and in driving meningococcal vaccine innovation. Because no one should die or suffer from this ...

Fourth quarter and full year 2023 results were reviewed by management during a live audio webcast with the financial community on February 1st, 2024. The presentation was followed by a Q&A session.

We chase the miracles of science to improve people’s lives, and sometimes that means starting over with Plan B, Plan C, or even Plan Z. This film brings together the inner thoughts and ambitions of ...

Sanofi US (Sanofi-Aventis U.S. LLC and Sanofi US Services Inc.) respects the interest that visitors to our websites have in understanding what information is collected electronically, how it is ...

We want to build a healthier, more resilient world. We turn the impossible into the possible by discovering, developing, and delivering medicines and vaccines for millions of people around the world.

Established in Australia in 1980, with a global heritage that spans 100 years, we invest in the health of Australians by pioneering science and medicine across therapeutic areas including immunology, ...

Third quarter 2024 results were reviewed by management during a conference call with the financial community on Friday October 25, 2024. The presentation was followed by a Q&A session. We’re proud to ...

Vaccines are a key driver of company growth. Our goal is to bring 10 new vaccine candidates into clinical trials by 2025. This ambition is fueled by investments in best-in-class science and our mRNA ...

Women represent 49% of our overall workforce and 42% of senior management. So, we’ve committed to transforming our culture, development, recruitment, and succession planning to ensure women represent ...